Jasper therapeutics inc JSPR.US 總覽分析
JSPR 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分低，若以價值投資為目標且有長期投資部位，需要嚴格執行自己的出場計畫來減持部位
JSPR 近期報酬表現
-3.33%
Jasper therapeutics inc
1.99%
同產業平均
-0.64%
S&P500
與 JSPR 同產業的標的表現
- IMNM Immunome inc價值 1 分趨勢 3 分波段 5 分籌碼 3 分股利 1 分查看更多
JSPR 公司資訊
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.